Generic placeholder image

Current Cancer Drug Targets


ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Review Article

Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy

Author(s): Jie Wu, Dingxin Di, Chen Zhao, Yingyi Liu, Hongxia Chen, Yan Gong, Xianda Zhao and Honglei Chen*

Volume 18, Issue 6, 2018

Page: [558 - 566] Pages: 9

DOI: 10.2174/1568009618666171129223533

Price: $65


Glioma-associated oncogenes (GLIs) are zinc finger protein family members and downstream regulatory factors of the classic Hedgehog (Hh) signaling pathway. GLI proteins influence the growth and development of organisms and aid in tissue repair. However, aberrant expression of the GLI family member GLI1 promotes carcinogenesis by inducing epithelial–mesenchymal transition (EMT), angiogenesis, and other signaling pathways. Overexpression of GLI1 is thought to be an indicator of poor prognosis as well as a potential therapeutic target for cancers. GLI inhibitors such as zerumbone, GANT61, resveratrol, and cyclopamine depress the Hh pathway in vitro and in vivo cancer research, and other non-canonical pathways may also activate expression of GLI1. Here, we summarize GLI function in carcinogenesis and cancer-targeted therapy.

Keywords: Hedgehog signaling, GLI proteins, carcinogenesis, targeted therapy, non-canonical pathways, mutation.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy